```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:sssptal642cxy

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09  ZDB will be removed from STN
 NEWS  5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS  6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS  7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03  New e-mail delivery for search results now available
 NEWS 10  Jun 10  MEDLINE Reload
 NEWS 11  Jun 10  PCTFULL has been reloaded
 NEWS 12  Jul 02  FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14  Jul 29  Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30  NETFIRST to be removed from STN
 NEWS 16  Aug 08  CANCERLIT reload
 NEWS 17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08  NTIS has been reloaded and enhanced
 NEWS 19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
 NEWS 20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26  Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03  JAPIO has been reloaded and enhanced

 NEWS EXPRESS  February 1 CURRENT WINDOWS VERSION IS V6.0d,
               CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:31:47 ON 11 SEP 2002

=> file uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'USPATFULL' ENTERED AT 07:32:03 ON 11 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 10 Sep 2002 (20020910/PD)
FILE LAST UPDATED: 10 Sep 2002 (20020910/ED)
HIGHEST GRANTED PATENT NUMBER: US6449768
HIGHEST APPLICATION PUBLICATION NUMBER: US2002124292
CA INDEXING IS CURRENT THROUGH 10 Sep 2002 (20020910/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 10 Sep 2002 (20020910/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2002
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2002

>>>  USPAT2 is now available.  USPATFULL contains full text of the     <<<
>>>  original, i.e., the earliest published granted patents or         <<<
>>>  applications.  USPAT2 contains full text of the latest US         <<<
>>>  publications, starting in 2001, for the inventions covered in     <<<
>>>  USPATFULL.  A USPATFULL record contains not only the original     <<<
>>>  published document but also a list of any subsequent              <<<
>>>  publications.  The publication number, patent kind code, and      <<<
>>>  publication date for all the US publications for an invention     <<<
>>>  are displayed in the PI (Patent Information) field of USPATFULL   <<<
>>>  records and may be searched in standard search fields, e.g., /PN, <<<
>>>  /PK, etc.                                                         <<<

>>>  USPATFULL and USPAT2 can be accessed and searched together         <<<
>>>  through the new cluster USPATALL.  Type FILE USPATALL to          <<<
>>>  enter this cluster.                                               <<<
>>>                                                                    <<<
>>>  Use USPATALL when searching terms such as patent assignees,       <<<
>>>  classifications, or claims, that may potentially change from      <<<
>>>  the earliest to the latest publication.                           <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s hsp70 or heat shock protein 70
          755 HSP70
       770260 HEAT
        47354 HEATS
       776269 HEAT
                 (HEAT OR HEATS)
       131043 SHOCK
        24872 SHOCKS
       143087 SHOCK
                 (SHOCK OR SHOCKS)
       118760 PROTEIN
        97209 PROTEINS
       138809 PROTEIN
                 (PROTEIN OR PROTEINS)
      1234377 70
          161 HEAT SHOCK PROTEIN 70
                 (HEAT(W)SHOCK(W)PROTEIN(W)70)
L1        820 HSP70 OR HEAT SHOCK PROTEIN 70

=> s l1 and adjuvant
        30044 ADJUVANT
        37879 ADJUVANTS
```

```
        54394 ADJUVANT
              (ADJUVANT OR ADJUVANTS)
L2        340 L1 AND ADJUVANT

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3         340 DUP REM L2 (0 DUPLICATES REMOVED)

=> s l3 not py=>1999
L4         340 S L3
       816008 PY=>1999
L5          46 L4 NOT PY=>1999

=> d l5 1-10 ab

L5   ANSWER 1 OF 46  USPATFULL
AB     A protein, Leukocyte Derived Growth Factor 2 (hereinafter LDGF2) having
       PDGF-like activity is described. LDGF2 reacts with PDGF receptors and
       possesses mitogenic and/or chemotactic activity for various cell types,
       particularly connective tissue cells. LDGF2 may be used as the active
       ingredient in therapeutic compositions, e.g. wound healing compositions,
       or even further may be used as an additive to cell culture media for the
       purpose of stimulating cell growth. The protein has a molecular weight
       of about 7000 daltons determined by SDS gel electrophoresis and is about
       61 amino acids in length.

L5   ANSWER 2 OF 46  USPATFULL
AB     Disclosed is a Drosophila grim gene and encoded GRIM polypeptide, an
       activator of apoptosis. The disclosed nucleic acid sequences are useful
       in the production of the protein and as hybridization probes and
       primers. Expression of the GRIM protein causes programmed cell death.
       Preferred embodiments include expression of grim under the control of an
       inducible promoter and the use of such a construct in the control of an
       insect population.

L5   ANSWER 3 OF 46  USPATFULL
AB     Disclosed is a method for determining whether a test protein is capable
       of interacting with a nuclear hormone receptor protein. The method
       involves: (a) providing a host cell which contains (i) a reporter gene
       operably linked to a protein binding site; (ii) a first fusion gene
       which expresses a first fusion protein, the first fusion protein
       including a nuclear hormone receptor protein covalently bonded to a
       binding moiety which is capable of specifically binding to the protein
       binding site; and (iii) a second fusion gene which expresses a second
       fusion protein, the second fusion protein including the test protein
       covalently bonded to a weak gene activating moiety; and (b) determining
       whether the test protein increases expression of the reporter gene as an
       indication of its ability to interact with the nuclear hormone receptor
       protein. Such an interaction may be hormone dependent, hormone
       independent, or hormone sensitive. Also disclosed is purified DNA
       encoding thyroid hormone receptor-interacting proteins and the
       polypeptides expressed from such DNA.

L5   ANSWER 4 OF 46  USPATFULL
AB     The present invention concerns the discovery that proteins encoded by a
       family of vertebrate genes, termed here hedgehog-related genes, comprise
       morphogenic signals produced by embryonic patterning centers, and are
       involved in the formation of ordered spatial arrangements of
       differentiated tissues in vertebrates. The present invention makes
       available compositions and methods that can be utilized, for example to
       generate and/or maintain an array of different vertebrate tissue both in
       vitro and in vivo.

L5   ANSWER 5 OF 46  USPATFULL
AB     The present invention relates to the use of a group of propargylamines
       of the general formula (I) ##STR1## wherein R.sup.1 is hydrogen or
       CH.sub.3 and R.sup.2 is (CH.sub.2).sub.n CH.sub.3 and n is an integer
       from 0 to 16, and salts thereof, as cellular rescue agents in the
       treatment and prevention of diseases in which cell death occurs by
       apoptosis. Some of the compounds of formula I are novel. The invention
       is also directed to the use of these compounds in the treatment of these
       diseases, as well as to processes for the preparation of the compounds.

L5   ANSWER 6 OF 46  USPATFULL
AB     The present invention relates to methods and compositions for eliciting
       an immune response and the prevention and treatment of primary and
       metastatic neoplastic diseases and infectious diseases. The methods of
       the invention comprise administering a composition comprising an
       effective amount of a complex, in which the complex consists essentially
       of a heat shock protein (hsp) noncovalently bound to an antigenic
       molecule. "Antigenic molecule" as used herein refers to the peptides
       with which the hsps are endogenously associated in vivo as well as
       exogenous antigens/immunogens (i.e., with which the hsps are not
       complexed in vivo) or antigenic/immunogenic fragments and derivatives
       thereof. In a preferred embodiment, the complex is autologous to the
       individual. The effective amounts of the complex are in the range of
       10-600 micrograms for complexes comprising hsp70, 50-1000
       micrograms for hsp90, and 10-600 micrograms for gp96. The invention also
       provides a method for measuring tumor rejection in vivo in an
       individual, preferably a human, comprising measuring the generation by
       the individual of MHC Class I-restricted CD8+ cytotoxic T lymphocytes
       specific to the tumor. Methods of purifying hsp70-peptide
       complexes are also provided.

L5   ANSWER 7 OF 46  USPATFULL
AB     Methods and compositions for treating CF by mobilizing mutant forms of
       CFTR, which retain at least some functional activity, to the plasma
       membrane where they can mediate chloride ion transport are disclosed.

L5   ANSWER 8 OF 46  USPATFULL
AB     The present invention provides a human cofactor A-like protein (COAPR)
       and polynucleotides which identify and encode COAPR. The invention also
       provides expression vectors, host cells, agonists, antibodies and
       antagonists. The invention also provides methods for treating disorders
       associated with expression of COAPR.

L5   ANSWER 9 OF 46  USPATFULL
AB     Attenuated vaccinia or canarypox recombinant viruses containing DNA
       coding for a cytokine and/or a tumor associated antigen, as well as
       methods and compositions employing the viruses, are disclosed and
       claimed. The recombinant viruses can be NYVAC or ALVAC recombinant
       viruses. The DNA can code for at least one of: human tumor necrosis
       factor; nuclear phosphoprotein p53, wildtype or mutant; human
       melanoma-associated antigen; IL-2; IFN.gamma.; IL-4; GMCSF; IL-12; B7;
       erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene
       products therefrom are useful for cancer therapy.

L5   ANSWER 10 OF 46  USPATFULL
AB     The present invention relates to recombinant mycobacteria, particularly
       recombinant M. bovis BCG, which express heterologous DNA encoding a
       product (protein or polypeptide) of interest, such a protein or
       polypeptide (e.g., an antigen) against which an immune response is
       desired, or a cytokine.


=> d 1-10 ibib

L5   ANSWER 1 OF 46  USPATFULL
```

ACCESSION NUMBER: 1998:157146 USPATFULL
TITLE: DNA encoding leukocyte derived growth factor-2 (LDGF-2)
INVENTOR(S): Grotendorst, Gary R., Miami, FL, United States
Iida, Naoko, Miami Beach, FL, United States
PATENT ASSIGNEE(S): University of South Florida, Tampa, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849534		19981215
APPLICATION INFO.:	US 1995-465095		19950605 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-179656, filed on 7 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-1177, filed on 7 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1990-472377, filed on 1 Feb 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kemmerer, Elizabeth C.
LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Hanley, Elizabeth A.
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 1666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 46 USPATFULL
ACCESSION NUMBER: 1998:154085 USPATFULL
TITLE: Invertebrate apoptosis gene `GRIM` and methods of producing the protein encoded thereby
INVENTOR(S): Abrams, John M., Dallas, TX, United States
Chen, Po, Dallas, TX, United States
Nordstrom, William, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5846768		19981208
APPLICATION INFO.:	US 1996-684101		19960722 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kemmerer, Elizabeth C.
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 2475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 46 USPATFULL
ACCESSION NUMBER: 1998:154029 USPATFULL
TITLE: Nuclear hormone receptor-interacting polypeptides and related molecules and methods
INVENTOR(S): Moore, David D., Hingham, MA, United States
Lee, Jae Woon, Somerville, MA, United States
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5846711		19981208
APPLICATION INFO.:	US 1994-222719		19940404 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-969136, filed on 30 Oct 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Clark & Elbing LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 39 Drawing Figure(s); 37 Drawing Page(s)
LINE COUNT: 1810
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 46 USPATFULL
ACCESSION NUMBER: 1998:151078 USPATFULL
TITLE: Vertebrate embryonic pattern-inducing proteins, and uses related thereto
INVENTOR(S): Ingham, Philip W., Summertown, England
McMahon, Andrew P., Lexington, MA, United States
Tabin, Clifford J., Cambridge, MA, United States
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5844079		19981201
APPLICATION INFO.:	US 1994-356060		19941214 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-176427, filed on 30 Dec 1993
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Sorensen, Kenneth H.
LEGAL REPRESENTATIVE: Vincent, Matthew P., Arnold, Beth E.Foley, Hoag & Eliot LLP
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 7618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 46 USPATFULL
ACCESSION NUMBER: 1998:147687 USPATFULL
TITLE: Aliphatic propargylamines as cellular rescue agents
INVENTOR(S): Durden, David, Saskatoon, Canada
Paterson, Alick, Saskatoon, Canada
Davis, Bruce, Saskatoon, Canada
Dyck, Lillian, Saskatoon, Canada
Yu, Peter, Saskatoon, Canada
Li, Xinmin, Saskatoon, Canada
Boulton, Alan, Saskatoon, Canada
PATENT ASSIGNEE(S): University of Saskatchewan, Saskatoon, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5840979		19981124
APPLICATION INFO.:	US 1997-891904		19970714 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Burn, Brian M.
LEGAL REPRESENTATIVE: Synnestvedt & Lechner
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 867
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 46 USPATFULL
ACCESSION NUMBER: 1998:143661 USPATFULL
TITLE: Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
INVENTOR(S): Srivastava, Pramod K., Riverdale, NY, United States
PATENT ASSIGNEE(S): Fordham University, Bronx, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5837251		19981117
APPLICATION INFO.:	US 1995-527391		19950913 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Bansal, Gee Tha D.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1,8,16
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2361
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 46 USPATFULL
ACCESSION NUMBER: 1998:138855 USPATFULL
TITLE: Methods and compositions for treating cystic fibrosis
INVENTOR(S): Cheng, Seng Hing, Wellesley, MA, United States
Jiang, Canwen, Marlboro, MA, United States
PATENT ASSIGNEE(S): Genzyme Corporation, Framingham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834421		19981110
APPLICATION INFO.:	US 1997-807398		19970227 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Celsa, Bennett
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 635
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 46 USPATFULL
ACCESSION NUMBER: 1998:138682 USPATFULL
TITLE: Polynucleotides encoding a cofactor A-like protein
INVENTOR(S): Hillman, Jennifer L., San Jose, CA, United States
Goli, Surya K., Sunnyvale, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834239		19981110
APPLICATION INFO.:	US 1997-825782		19970408 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kemmerer, Elizabeth C.
ASSISTANT EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Mohan-Peterson, Sheela, Billings, Lucy J.Incyte Pharmaceuticals, Inc.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 46 USPATFULL
ACCESSION NUMBER: 1998:138427 USPATFULL
TITLE: Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
INVENTOR(S): Paoletti, Enzo, Delmar, NY, United States
Tartaglia, James, Schenectady, NY, United States
Cox, William I., Troy, NY, United States
PATENT ASSIGNEE(S): Virogenetics Corporation, Troy, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5833975		19981110
APPLICATION INFO.:	US 1994-184009		19940119 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-7115, filed on 21 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-847951, filed on 6 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-713967, filed on 11 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-666056, filed on 7 Mar 1991, now abandoned , said Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 1991-805567, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-638080, filed on 7 Jan 1991, now abandoned , said Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 1992-847977, filed on 3 Mar 1992, now abandoned which is a division of Ser. No. US 1990-478179, filed on 14 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-320471, filed on 8 Mar 1989, now patented, Pat. No. US 5155020
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Crouch, Deborah
LEGAL REPRESENTATIVE: Frommer Lawerence & Haug LLP, Frommer, William S., Kowalski, Thomas J.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 46 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 8834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 46 USPATFULL
ACCESSION NUMBER: 1998:134636 USPATFULL
TITLE: Recombinant mycobacterial vaccines
INVENTOR(S): Aldovini, Anna, Winchester, MA, United States
Young, Richard A., Winchester, MA, United States
PATENT ASSIGNEE(S): Whitehead Institute for Biomedical Research, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5830475		19981103
APPLICATION INFO.:	US 1995-460981		19950605 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-96027, filed on 22 Jul 1993, now patented, Pat. No. US 5591632 which is a continuation-in-part of Ser. No. US 1991-711334, filed on 6 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-367894, filed on 19 Jun 1989, now abandoned , said Ser. No. US 711334 which is a continuation-in-part of Ser. No. US 1989-361944, filed on 5 Jun 1989, now patented, Pat. No. US 5504005 which is a continuation-in-part of Ser. No. US 1988-223089, filed on 22 Jul 1988, now abandoned And Ser. No. US 1988-216390, filed on 7 Jul 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-163546, filed on 3 Mar 1988, now abandoned , said Ser. No. US 223089 which is a continuation-in-part of Ser. No. US 163546 which is a continuation-in-part of Ser. No. US 1987-20451, filed on 2 Mar 1987, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Railey, II, Johnny F.
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 1-10 ibib ab

L5 ANSWER 1 OF 46 USPATFULL
ACCESSION NUMBER: 1998:157146 USPATFULL
TITLE: DNA encoding leukocyte derived growth factor-2 (LDGF-2)
INVENTOR(S): Grotendorst, Gary R., Miami, FL, United States
Iida, Naoko, Miami Beach, FL, United States
PATENT ASSIGNEE(S): University of South Florida, Tampa, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849534		19981215
APPLICATION INFO.:	US 1995-465095		19950605 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-179656, filed on 7 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-1177, filed on 7 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1990-472377, filed on 1 Feb 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kemmerer, Elizabeth C.
LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Hanley, Elizabeth A.
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 1666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A protein, Leukocyte Derived Growth Factor 2 (hereinafter LDGF2) having PDGF-like activity is described. LDGF2 reacts with PDGF receptors and possesses mitogenic and/or chemotactic activity for various cell types, particularly connective tissue cells. LDGF2 may be used as the active ingredient in therapeutic compositions, e.g. wound healing compositions, or even further may be used as an additive to cell culture media for the purpose of stimulating cell growth. The protein has a molecular weight of about 7000 daltons determined by SDS gel electrophoresis and is about 61 amino acids in length.

L5 ANSWER 2 OF 46 USPATFULL
ACCESSION NUMBER: 1998:154085 USPATFULL
TITLE: Invertebrate apoptosis gene `GRIM` and methods of producing the protein encoded thereby
INVENTOR(S): Abrams, John M., Dallas, TX, United States
Chen, Po, Dallas, TX, United States
Nordstrom, William, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5846768		19981208
APPLICATION INFO.:	US 1996-684101		19960722 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kemmerer, Elizabeth C.
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 2475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a Drosophila grim gene and encoded GRIM polypeptide, an activator of apoptosis. The disclosed nucleic acid sequences are useful in the production of the protein and as hybridization probes and primers. Expression of the GRIM protein causes programmed cell death. Preferred embodiments include expression of grim under the control of an inducible promoter and the use of such a construct in the control of an insect population.

L5 ANSWER 3 OF 46 USPATFULL
ACCESSION NUMBER: 1998:154029 USPATFULL
TITLE: Nuclear hormone receptor-interacting polypeptides and related molecules and methods
INVENTOR(S): Moore, David D., Hingham, MA, United States
Lee, Jae Woon, Somerville, MA, United States
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5846711		19981208
APPLICATION INFO.:	US 1994-222719		19940404 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-969136, filed on 30 Oct 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Clark & Elbing LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 39 Drawing Figure(s); 37 Drawing Page(s)
LINE COUNT: 1810
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a method for determining whether a test protein is capable of interacting with a nuclear hormone receptor protein. The method involves: (a) providing a host cell which contains (i) a reporter gene operably linked to a protein binding site; (ii) a first fusion gene which expresses a first fusion protein, the first fusion protein

including a nuclear hormone receptor protein covalently bonded to a binding moiety which is capable of specifically binding to the protein binding site; and (iii) a second fusion gene which expresses a second fusion protein, the second fusion protein including the test protein covalently bonded to a weak gene activating moiety; and (b) determining whether the test protein increases expression of the reporter gene as an indication of its ability to interact with the nuclear hormone receptor protein. Such an interaction may be hormone dependent, hormone independent, or hormone sensitive. Also disclosed is purified DNA encoding thyroid hormone receptor-interacting proteins and the polypeptides expressed from such DNA.

L5 ANSWER 4 OF 46 USPATFULL
ACCESSION NUMBER: 1998:151078 USPATFULL
TITLE: Vertebrate embryonic pattern-inducing proteins, and uses related thereto
INVENTOR(S): Ingham, Philip W., Summertown, England
McMahon, Andrew P., Lexington, MA, United States
Tabin, Clifford J., Cambridge, MA, United States
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5844079		19981201
APPLICATION INFO.:	US 1994-356060		19941214 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-176427, filed on 30 Dec 1993		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Walsh, Stephen		
ASSISTANT EXAMINER:	Sorensen, Kenneth H.		
LEGAL REPRESENTATIVE:	Vincent, Matthew P., Arnold, Beth E.Foley, Hoag & Eliot LLP		
NUMBER OF CLAIMS:	41		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 21 Drawing Page(s)		
LINE COUNT:	7618		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.

L5 ANSWER 5 OF 46 USPATFULL
ACCESSION NUMBER: 1998:147687 USPATFULL
TITLE: Aliphatic propargylamines as cellular rescue agents
INVENTOR(S): Durden, David, Saskatoon, Canada
Paterson, Alick, Saskatoon, Canada
Davis, Bruce, Saskatoon, Canada
Dyck, Lillian, Saskatoon, Canada
Yu, Peter, Saskatoon, Canada
Li, Xinmin, Saskatoon, Canada
Boulton, Alan, Saskatoon, Canada
PATENT ASSIGNEE(S): University of Saskatchewan, Saskatoon, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5840979		19981124
APPLICATION INFO.:	US 1997-891904		19970714 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Burn, Brian M.		
LEGAL REPRESENTATIVE:	Synnestvedt & Lechner		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	867		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of a group of propargylamines of the general formula (I) ##STR1## wherein R.sup.1 is hydrogen or CH.sub.3 and R.sup.2 is (CH.sub.2).sub.n CH.sub.3 and n is an integer from 0 to 16, and salts thereof, as cellular rescue agents in the treatment and prevention of diseases in which cell death occurs by apoptosis. Some of the compounds of formula I are novel. The invention is also directed to the use of these compounds in the treatment of these diseases, as well as to processes for the preparation of the compounds.

L5 ANSWER 6 OF 46 USPATFULL
ACCESSION NUMBER: 1998:143661 USPATFULL
TITLE: Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
INVENTOR(S): Srivastava, Pramod K., Riverdale, NY, United States
PATENT ASSIGNEE(S): Fordham University, Bronx, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5837251		19981117
APPLICATION INFO.:	US 1995-527391		19950913 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
ASSISTANT EXAMINER:	Bansal, Gee Tha D.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1,8,16		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	2361		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10-600 micrograms for complexes comprising **hsp70**, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96. The invention also provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MHC Class I-restricted CD8+ cytotoxic T lymphocytes specific to the tumor. Methods of purifying **hsp70**-peptide complexes are also provided.

L5 ANSWER 7 OF 46 USPATFULL
ACCESSION NUMBER: 1998:138855 USPATFULL

TITLE: Methods and compositions for treating cystic fibrosis
INVENTOR(S): Cheng, Seng Hing, Wellesley, MA, United States
Jiang, Canwen, Marlboro, MA, United States
PATENT ASSIGNEE(S): Genzyme Corporation, Framingham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834421		19981110
APPLICATION INFO.:	US 1997-807398		19970227 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Celsa, Bennett
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 635
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for treating CF by mobilizing mutant forms of CFTR, which retain at least some functional activity, to the plasma membrane where they can mediate chloride ion transport are disclosed.

L5 ANSWER 8 OF 46 USPATFULL
ACCESSION NUMBER: 1998:138682 USPATFULL
TITLE: Polynucleotides encoding a cofactor A-like protein
INVENTOR(S): Hillman, Jennifer L., San Jose, CA, United States
Goli, Surya K., Sunnyvale, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834239		19981110
APPLICATION INFO.:	US 1997-825782		19970408 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kemmerer, Elizabeth C.
ASSISTANT EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Mohan-Peterson, Sheela, Billings, Lucy J.Incyte Pharmaceuticals, Inc.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a human cofactor A-like protein (COAPR) and polynucleotides which identify and encode COAPR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of COAPR.

L5 ANSWER 9 OF 46 USPATFULL
ACCESSION NUMBER: 1998:138427 USPATFULL
TITLE: Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
INVENTOR(S): Paoletti, Enzo, Delmar, NY, United States
Tartaglia, James, Schenectady, NY, United States
Cox, William I., Troy, NY, United States
PATENT ASSIGNEE(S): Virogenetics Corporation, Troy, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5833975		19981110
APPLICATION INFO.:	US 1994-184009		19940119 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-7115, filed on 21 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-847951, filed on 6 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-713967, filed on 11 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-666056, filed on 7 Mar 1991, now abandoned , said Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 1991-805567, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-638080, filed on 7 Jan 1991, now abandoned , said Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 1992-847977, filed on 3 Mar 1992, now abandoned which is a division of Ser. No. US 1990-478179, filed on 14 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-320471, filed on 8 Mar 1989, now patented, Pat. No. US 5155020
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Crouch, Deborah
LEGAL REPRESENTATIVE: Frommer Lawerence & Haug LLP, Frommer, William S., Kowalski, Thomas J.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 46 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 8834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Attenuated vaccinia or canarypox recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IFN.gamma.; IL-4; GMCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.

L5 ANSWER 10 OF 46 USPATFULL
ACCESSION NUMBER: 1998:134636 USPATFULL
TITLE: Recombinant mycobacterial vaccines
INVENTOR(S): Aldovini, Anna, Winchester, MA, United States
Young, Richard A., Winchester, MA, United States
PATENT ASSIGNEE(S): Whitehead Institute for Biomedical Research, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5830475		19981103
APPLICATION INFO.:	US 1995-460981		19950605 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-96027, filed on 22 Jul 1993, now patented, Pat. No. US 5591632 which is a continuation-in-part of Ser. No. US 1991-711334, filed on 6 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-367894, filed on 19 Jun 1989, now abandoned , said Ser. No. US 711334 which is a continuation-in-part of Ser. No. US 1989-361944, filed on 5 Jun 1989, now patented, Pat. No. US 5504005 which is a continuation-in-part of Ser. No. US 1988-223089, filed on 22 Jul 1988, now abandoned And Ser. No. US 1988-216390, filed on 7 Jul 1988, now abandoned which is a continuation-in-part of Ser. No.

US 1988-163546, filed on 3 Mar 1988, now abandoned , said Ser. No. US 223089 which is a continuation-in-part of Ser. No. US 163546 which is a continuation-in-part of Ser. No. US 1987-20451, filed on 2 Mar 1987, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Railey, II, Johnny F.
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine.

=> d his

(FILE 'HOME' ENTERED AT 07:31:47 ON 11 SEP 2002)

FILE 'USPATFULL' ENTERED AT 07:32:03 ON 11 SEP 2002
L1 820 S HSP70 OR HEAT SHOCK PROTEIN 70
L2 340 S L1 AND ADJUVANT
L3 340 DUP REM L2 (0 DUPLICATES REMOVED)
L4 340 S L3
L5 46 S L3 NOT PY=>1999

=> d l5 10-20 ibib ab

L5 ANSWER 10 OF 46 USPATFULL
ACCESSION NUMBER: 1998:134636 USPATFULL
TITLE: Recombinant mycobacterial vaccines
INVENTOR(S): Aldovini, Anna, Winchester, MA, United States
Young, Richard A., Winchester, MA, United States
PATENT ASSIGNEE(S): Whitehead Institute for Biomedical Research, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5830475		19981103
APPLICATION INFO.:	US 1995-460981		19950605 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-96027, filed on 22 Jul 1993, now patented, Pat. No. US 5591632 which is a continuation-in-part of Ser. No. US 1991-711334, filed on 6 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-367894, filed on 19 Jun 1989, now abandoned , said Ser. No. US 711334 which is a continuation-in-part of Ser. No. US 1989-361944, filed on 5 Jun 1989, now patented, Pat. No. US 5504005 which is a continuation-in-part of Ser. No. US 1988-223089, filed on 22 Jul 1988, now abandoned And Ser. No. US 1988-216390, filed on 7 Jul 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-163546, filed on 3 Mar 1988, now abandoned , said Ser. No. US 223089 which is a continuation-in-part of Ser. No. US 163546 which is a continuation-in-part of Ser. No. US 1987-20451, filed on 2 Mar 1987, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Railey, II, Johnny F.
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine.

L5 ANSWER 11 OF 46 USPATFULL
ACCESSION NUMBER: 1998:134628 USPATFULL
TITLE: Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
INVENTOR(S): Srivastava, Pramod K., Riverdale, NY, United States
PATENT ASSIGNEE(S): Fordham University, Bronx, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5830464		19981103
APPLICATION INFO.:	US 1997-796316		19970207 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: VanderVegt, F. Pierre
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
LINE COUNT: 2332
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule in combination with administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex when administered intradermally are in the range of 0.1 to 9.0 micrograms for complexes comprising **hsp70**, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96. In another embodiment, the effective amounts of the complex when administered subcutaneously are in the range of 10 to 600 micrograms for complexes comprising **hsp70**, 50 to 5000 micrograms for hsp90, and 10 to 600 micrograms for gp96.

L5 ANSWER 12 OF 46 USPATFULL
ACCESSION NUMBER: 1998:131609 USPATFULL
TITLE: In vitro activation of cytotoxic T cells

INVENTOR(S): Peterson, Per A., La Jolla, CA, United States
Jackson, Michael, Del Mar, CA, United States
Langlade-Demoyen, Pierre, Del Mar, CA, United States
PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5827737		19981027
APPLICATION INFO.:	US 1996-669685		19960624 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-209797, filed on 10 Mar 1994, now patented, Pat. No. US 5529921 which is a continuation of Ser. No. US 1992-841662, filed on 19 Feb 1992, now patented, Pat. No. US 5314813
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecila J.
ASSISTANT EXAMINER: VanderVegt, F. Pierre
LEGAL REPRESENTATIVE: Townsend & Townsend & Crew
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 3958
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CD8 cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human .beta.2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.

L5 ANSWER 13 OF 46 USPATFULL
ACCESSION NUMBER: 1998:119133 USPATFULL
TITLE: Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene
INVENTOR(S): Hoffman, Stephen L., Gaithersburg, MD, United States
Charoenvit, Yupin, Silver Spring, MD, United States
Hedstrom, Richard C., Gaithersburg, MD, United States
Doolan, Denise L., Rockville, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the Navy, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5814617		19980929
APPLICATION INFO.:	US 1994-319704		19941007 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Cunningham, Thomas M.
LEGAL REPRESENTATIVE: Spevack, A. David
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1590
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An IgG1 monoclonal antibody, Navy Yoelii Liver Stage 3 (NYLS3) does not recognize sporozoites, but recognizes P. yoelii liver stage parasites within 6 hours of invasion of mouse hepatocytes, and throughout the hepatic and asexual erythrocytic stages of the life cycle. When added to primary cultures of mouse hepatocytes 24 hours after inoculation with P. yoelii sporozoites, when all sporozoites have invaded hepatocytes, NYLS3 eliminates up to 98% of liver stage parasites. Intravenous injection of NYLS3 into mice delays the onset and reduces the density of blood stage parasitemia after sporozoite or blood stage challenge. The protein recognized by this mAb is identified and designated P. yoelii hepatic and erythrocytic stage protein, 17-kDa or PyHEP17. The gene encoding PyHEP17 and a DNA vaccine comprising exons of the DNA that encodes PyHEP17 are disclosed. A DNA vaccine consisting of exon 1 and part of exon 2 of the gene encoding PyHEP17 protects 86% of A/J mice, 33%-43% of B10.BR mice, 17%-29% of BALB/c mice and 14%-20% of B10.Q mice from development of blood-stage parasitemia. A combination of DNA vaccines consisting of a PyHEP17 DNA vaccine and a PyCSP DNA vaccine confers complete protection against development of blood-stage parasitemia in BALB/c mice and 71% protection in A/J and B10.BR mice. This DNA vaccine-induced protection may be additive. Combinations of other malaria antigens are covered. The application discloses the P. falciparum homolog of PyHEP17 and includes the means of identification of the PyHEP17 homologs of the other Plasmodium species which infect humans, specifically P. vivax, P. ovale and P. malariae.

L5 ANSWER 14 OF 46 USPATFULL
ACCESSION NUMBER: 1998:119003 USPATFULL
TITLE: Heat shock-like protein
INVENTOR(S): Hillman, Jennifer L., San Jose, CA, United States
Shah, Purvi, Sunnyvale, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5814481		19980929
APPLICATION INFO.:	US 1997-846134		19970425 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Bugalsky, Gabriele E.
LEGAL REPRESENTATIVE: Billings, Lucy J.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1943
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel heat shock-like protein (HSPRO) and polynucleotides which identify and encode HSPRO. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of HSPRO.

L5 ANSWER 15 OF 46 USPATFULL
ACCESSION NUMBER: 1998:111956 USPATFULL
TITLE: Inhibitors of IMPDH enzyme
INVENTOR(S): Armistead, David M., Maynard, MA, United States
Badia, Michael C., Bedford, MA, United States
Bemis, Guy W., Arlington, MA, United States
Bethiel, Randy S., Allston, MA, United States
Frank, Catharine A., Marlborough, MA, United States
Novak, Perry M., Milford, MA, United States
Ronkin, Steven M., Watertown, MA, United States
Saunders, Jeffrey O., Acton, MA, United States
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5807876		19980915

APPLICATION INFO.: US 1996-636361 19960423 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Govindaswamy, N.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel class of compounds which are IMPDH inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as agents for immunosuppression. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.

L5 ANSWER 16 OF 46 USPATFULL
ACCESSION NUMBER: 1998:101540 USPATFULL
TITLE: Human protein disulfide isomerase
INVENTOR(S): Braxton, Scott Michael, San Mateo, CA, United States
Murry, Lynn E., Portola Valley, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5798249		19980825
APPLICATION INFO.:	US 1996-650275		19960516 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-649740, filed on 15 May 1996
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Saidha, Tekchand
LEGAL REPRESENTATIVE: Billings, Lucy J.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2291
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a polynucleotide (pdih) the partial sequence for which was initially isolated from a lung cDNA library and which identifies and encodes a novel human protein disulfide isomerase (PDIH). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PDIH. The invention also provides for the use of purified PDIH and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the abnormal expression of PDIH. Additionally, the invention provides for the use of antisense molecules to pdih or inhibitors of PDIH in pharmaceutical compositions for treatment of diseases resulting secretion of PDIH. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of pdih, or anti-PDIH antibodies which specifically bind to the polypeptide, PDIH.

L5 ANSWER 17 OF 46 USPATFULL
ACCESSION NUMBER: 1998:92162 USPATFULL
TITLE: Vertebrate embryonic pattern-inducing proteins and uses related thereto
INVENTOR(S): Ingham, Philip W., Summertown, England
McMahon, Andrew P., Lexington, MA, United States
Tabin, Clifford J., Cambridge, MA, United States
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5789543		19980804
APPLICATION INFO.:	US 1993-176427		19931230 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Sorensen, Kenneth A.
LEGAL REPRESENTATIVE: Vincent, Matthew P., Arnold, Beth E.Foley, Hoag & Eliot LLP
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 4235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.

L5 ANSWER 18 OF 46 USPATFULL
ACCESSION NUMBER: 1998:91811 USPATFULL
TITLE: Detection of wheat that has experienced elevated temperatures during the grain filling period
INVENTOR(S): Bernardin, John E., El Sobrante, CA, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5789180		19980804
APPLICATION INFO.:	US 1995-543233		19951013 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-192873, filed on 7 Feb 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Grun, James L.
LEGAL REPRESENTATIVE: Silverstein, M. Howard, Fado, John D., Connor, Margaret A.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1,8
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 999

AB Methods for detecting heat-stressed wheat, that is, wheat that has experienced elevated temperatures during the grain filling period, and methods to assess end-use properties of wheat grain are disclosed. In the method to detect heat-stressed wheat, wheat heat stress peptide in a sample of wheat grain or flour is measured. Wheat grain or flour that has a level of wheat heat stress peptide two or more times greater that the constitutive level is determined to have experienced elevated temperatures during the grain filling period. In the method to assess an end-use property of wheat, wheat heat stress peptide in a sample of

wheat grain or flour is measured, and the level is compared to a calibration curve that correlates the level of wheat heat stress peptide and the end-use property.

L5 ANSWER 19 OF 46 USPATFULL
ACCESSION NUMBER: 1998:88652 USPATFULL
TITLE: Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
INVENTOR(S): Artavanis-Tsakonas, Spyridon, Hamden, CT, United States
Fehon, Richard Grant, Durham, NC, United States
Zagouras, Panayiotis, New Haven, CT, United States
Blaumueller, Christine Marie, New Haven, CT, United States
PATENT ASSIGNEE(S): Yale University, New Haven, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5786158		19980728
APPLICATION INFO.:	US 1993-83590		19930625 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-955012, filed on 30 Sep 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-879038, filed on 30 Apr 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 2
NUMBER OF DRAWINGS: 70 Drawing Figure(s); 68 Drawing Page(s)
LINE COUNT: 4658
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to diagnostic methods and compositions for detection of malignancy or nervous system disorders based on the level of Notch proteins or nucleic acids. Therapeutic methods and methods of inhibiting Notch expression are also provided.

L5 ANSWER 20 OF 46 USPATFULL
ACCESSION NUMBER: 1998:82345 USPATFULL
TITLE: Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents
INVENTOR(S): Cohen, Irun R., Rehovot, Israel
Elias, Dana, Rehovot, Israel
Markovits, Doron, Rehovot, Israel
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780034		19980714
APPLICATION INFO.:	US 1995-384454		19950203 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-937449, filed on 31 Aug 1992, now abandoned which is a continuation of Ser. No. US 1990-493127, filed on 14 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-371249, filed on 26 Jun 1989, now patented, Pat. No. US 5114844 which is a continuation-in-part of Ser. No. US 1989-322864, filed on 14 Mar 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Cunningham, Thomas M.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1667
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A 65 KD heat shock protein, proteins cross-reactive therewith, antibodies thereto or T cells specific thereto can be used for detecting in humans the existence of, a tendency to develop, or the initiation of a process leading to insulin dependent diabetes mellitus. Antibodies to hsp65 can be used to detect the hsp65 molecule in blood or urine. The hsp65 molecule of any species, or any other substance immunologically cross-reactive therewith, when administered with a tolerogenic carrier, can be used for the prevention or treatment of IDDM prior to development of clinical symptoms thereof. T cells, active fragments thereof or the receptor peptide thereof can also be used for prevention or treatment of IDDM.

=> d 20-30 ibib ab

L5 ANSWER 20 OF 46 USPATFULL
ACCESSION NUMBER: 1998:82345 USPATFULL
TITLE: Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents
INVENTOR(S): Cohen, Irun R., Rehovot, Israel
Elias, Dana, Rehovot, Israel
Markovits, Doron, Rehovot, Israel
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780034		19980714
APPLICATION INFO.:	US 1995-384454		19950203 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-937449, filed on 31 Aug 1992, now abandoned which is a continuation of Ser. No. US 1990-493127, filed on 14 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-371249, filed on 26 Jun 1989, now patented, Pat. No. US 5114844 which is a continuation-in-part of Ser. No. US 1989-322864, filed on 14 Mar 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Cunningham, Thomas M.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1667
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A 65 KD heat shock protein, proteins cross-reactive therewith, antibodies thereto or T cells specific thereto can be used for detecting in humans the existence of, a tendency to develop, or the initiation of a process leading to insulin dependent diabetes mellitus. Antibodies to hsp65 can be used to detect the hsp65 molecule in blood or urine. The hsp65 molecule of any species, or any other substance immunologically cross-reactive therewith, when administered with a tolerogenic carrier, can be used for the prevention or treatment of IDDM prior to development of clinical symptoms thereof. T cells, active fragments thereof or the receptor peptide thereof can also be used for prevention or treatment of IDDM.

L5 ANSWER 21 OF 46 USPATFULL
ACCESSION NUMBER: 1998:78722 USPATFULL
TITLE: Recombinant mycobacterial vaccines

INVENTOR(S): O'Donnell, Michael A., Sudbury, MA, United States
Duda, Rosemary B., Carlisle, MA, United States
DeWolf, William C., Southborough, MA, United States
Aldovini, Anna, Winchester, MA, United States
Young, Richard A., Winchester, MA, United States
PATENT ASSIGNEE(S): Beth Israel Hospital Association, Boston, MA, United States (U.S. corporation)
Whitehead Institute for Biomedical Research, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5776465		19980707
APPLICATION INFO.:	US 1995-461725		19950605 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-96027, filed on 22 Jul 1993, now patented, Pat. No. US 5591632 which is a continuation-in-part of Ser. No. US 1991-711334, filed on 6 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-367894, filed on 19 Jun 1989, now abandoned And Ser. No. US 1989-361944, filed on 5 Jun 1989, now patented, Pat. No. US 5504005 which is a continuation-in-part of Ser. No. US 1988-223089, filed on 22 Jul 1988, now abandoned And Ser. No. US 1988-216390, filed on 7 Jul 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-163546, filed on 3 Mar 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-20451, filed on 2 Mar 1987 , said Ser. No. US -223089 which is a continuation-in-part of Ser. No. US -163546
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Railey, II, Johnny F.
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1232
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine.

L5 ANSWER 22 OF 46 USPATFULL
ACCESSION NUMBER: 1998:72255 USPATFULL
TITLE: Recombinant poxviruses with foreign DNA in essential regions
INVENTOR(S): Falkner, Falko-Gunter, Vienna, Austria
Holzer, Georg, Vienna, Austria
Dorner, Friedrich, Vienna, Austria
PATENT ASSIGNEE(S): Immuno Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5770212		19980623
APPLICATION INFO.:	US 1997-802985		19970221 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-616133, filed on 14 Mar 1996 which is a continuation-in-part of Ser. No. US 1994-235392, filed on 29 Apr 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Mosher, Mary E.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1266
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Defective poxviruses that lack a function imparted by an essential region of its parental poxvirus are provided for protein production and vaccination. A DNA polynucleotide encoding a protein is inserted into the defective poxvirus and placed under transcriptional control of a promoter. The defective poxvirus is viable when the lost function of the essential region is complemented by a host cell, transgenic animal or helper virus.

L5 ANSWER 23 OF 46 USPATFULL
ACCESSION NUMBER: 1998:68807 USPATFULL
TITLE: recombinant poxviruses with foreign DNA in essential regions
INVENTOR(S): Falkner, Falko-Gunter, Vienna, Austria
Holzer, Georg, Vienna, Austria
Dorner, Friedrich, Vienna, Austria
PATENT ASSIGNEE(S): Immuno Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5766882		19980616
APPLICATION INFO.:	US 1996-616133		19960314 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-235392, filed on 29 Apr 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Campell, Bruce R.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1322
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Defective poxviruses that lack a function imparted by an essential region of its parental poxvirus are provided for protein production and vaccination. A DNA polynucleotide encoding a protein is inserted into the defective poxvirus and placed under transcriptional control of a promoter. The defective poxvirus is viable when the lost function of the essential region is complemented by a host cell, transgenic animal or helper virus.

L5 ANSWER 24 OF 46 USPATFULL
ACCESSION NUMBER: 1998:57767 USPATFULL
TITLE: Cell stress transcriptional factors
INVENTOR(S): Wu, Carl, Bethesda, MD, United States
Clos, Joachim, Bethesda, MD, United States
Westwood, J. Timothy, Rockville, MD, United States
Rabindran, Sridhar, Silver Spring, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5756343		19980526
APPLICATION INFO.:	US 1994-178477		19940107 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1990-617910, filed on 26 Nov 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Low, Christopher S. F.
LEGAL REPRESENTATIVE: Morgan & Finnegan, L.L.P.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 44 Drawing Figure(s); 28 Drawing Page(s)
LINE COUNT: 1762
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to DNA sequence coding for part or all of the heat shock transcription factor or heat shock factor (HSF) proteins derived from humans and Drosophila, and the proteins encoded by these sequences.

The present invention also includes methods for detecting HSF in a biological sample. The presence of HSF in the nucleus of a cell can be detected with specific anti-HSF antibody reagents. The presence of such HSF proteins in the nucleus indicates a stressed condition including diseases. Furthermore, the presence of multimeric HSF in the crude or fractionated cell extract is indicative of a stressed state.

L5 ANSWER 25 OF 46 USPATFULL
ACCESSION NUMBER: 1998:51728 USPATFULL
TITLE: Deltex proteins
INVENTOR(S): Artavanis-Tsakonas, Spyridon, Hamden, CT, United States
Busseau, Isabelle, Bures-Sur-Yvette, France
Diederich, Robert J., New Haven, CT, United States
Xu, Tian, Guilford, CT, United States
Matsuno, Kenji, New Haven, CT, United States
PATENT ASSIGNEE(S): Yale University, New Haven, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5750652		19980512
APPLICATION INFO.:	US 1994-185432		19940121 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Sorensen, Kenneth A.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 58 Drawing Figure(s); 40 Drawing Page(s)
LINE COUNT: 4194
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to amino acid sequences of the encoded deltex protein. The invention further relates to fragments and other derivatives, and analogs, of deltex proteins. In specific embodiments, the invention relates to deltex protein derivatives and analogs of the invention which are functionally active, or which comprise one or more domains of a deltex protein, including but not limited to the Gln-rich clusters, SH3 binding domains, domains which mediate binding to Notch or to a Notch derivative containing Notch cdc10/SW16/ankyrin ("ANK") repeats, domains which mediate binding to a second deltex protein, or any combination of the foregoing. The present invention also relates to compositions based on deltex proteins.

L5 ANSWER 26 OF 46 USPATFULL
ACCESSION NUMBER: 1998:51204 USPATFULL
TITLE: Immunotherapeutic stress protein-peptide complexes against cancer
INVENTOR(S): Srivastava, Pramod K., Riverdale, NY, United States
PATENT ASSIGNEE(S): Mount Sinai School of Medicine Of The City University of New York, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5750119		19980512
APPLICATION INFO.:	US 1994-315892		19940930 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-180685, filed on 13 Jan 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1,2
LINE COUNT: 1097
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a method for inhibiting the proliferation of a tumor in a mammal. The method involves the steps of (a) isolating a stress protein-peptide complex from tumor cells previously removed from the mammal and (b) administering the isolated stress protein-peptide complex back to the mammal in order to stimulate in the mammal an immune response against the tumor from which the complex was isolated. Stress protein-peptide complexes having particular utility in the practice of the instant invention include the **Hsp70**-peptide, Hsp90-peptide and gp96-peptide complexes.

L5 ANSWER 27 OF 46 USPATFULL
ACCESSION NUMBER: 1998:48564 USPATFULL
TITLE: P53AS protein and antibody therefor
INVENTOR(S): Kulesz-Martin, Molly F., Buffalo, NY, United States
PATENT ASSIGNEE(S): Health Research, Inc., Buffalo, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5747650		19980505
APPLICATION INFO.:	US 1996-644456		19960510 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-100496, filed on 2 Aug 1993
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
ASSISTANT EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Dunn, Michael L.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1580
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, we have discovered and purified a protein designated herein as p53as, which protein is present in normal cells of a mammal and is essentially identical to known normal growth controlling protein p53 of the same mammal, at least until the final 50 amino acids of the carboxy terminal end of the protein. The invention further includes an antibody specific for protein p53as, which antibody is designated herein as Ab p53as. The antibody may be either a monoclonal or polyclonal antibody and may be specific for p53as of any particular mammal such as mice and humans.

L5 ANSWER 28 OF 46 USPATFULL

ACCESSION NUMBER: 1998:45097 USPATFULL
TITLE: Method and device for diagnosing and distinguishing chest pain in early onset thereof
INVENTOR(S): Jackowski, George, Inglewood, Canada
PATENT ASSIGNEE(S): Spectral Diagnostics Inc., Toronto, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5744358		19980428
APPLICATION INFO.:	US 1996-707594		19960905 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-420298, filed on 11 Apr 1995, now patented, Pat. No. US 5604105 which is a continuation-in-part of Ser. No. US 1993-26453, filed on 3 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-695381, filed on 3 May 1991, now patented, Pat. No. US 5290678, issued on 1 Mar 1994

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1990-2027434	19901012

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wolski, Susan
LEGAL REPRESENTATIVE: Klauber & Jackson
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2396
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A diagnostic test, and a device for conducting the test, for assessing whether patient chest pain is cardiac in origin and for differentiating between unstable angina and myocardial infarction as a cause of patient chest pain is described. The diagnostic test comprises simultaneously detecting at least three selected cardiac markers with the use of at least three different monoclonal or polyclonal antibody pairs, each member of which is complementary to a different marker, which is released by heart muscle at varying stages after the onset of chest pain and is indicative of the cause of the chest pain.

L5 ANSWER 29 OF 46 USPATFULL
ACCESSION NUMBER: 1998:36577 USPATFULL
TITLE: Vectors and prokaryotes which autocatalytically delete antibiotic resistance
INVENTOR(S): Haun, Shirley L., Gaithersburg, MD, United States
Stover, Charles K., Mercer Island, WA, United States
Hatfull, Graham, Pittsburgh, PA, United States
Hanson, Mark S., Columbia, MD, United States
Jacobs, William R., City Island, NY, United States
PATENT ASSIGNEE(S): MedImmune, Inc., Gaithersburg, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5736367		19980407
APPLICATION INFO.:	US 1995-425380		19950420 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-861002, filed on 31 Mar 1992

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fleisher, Mindy
ASSISTANT EXAMINER: Weiss, Bonnie D.
LEGAL REPRESENTATIVE: Herron, Charles J., Olstein, Elliot M.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 42 Drawing Figure(s); 39 Drawing Page(s)
LINE COUNT: 1027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A vector and a prokaryote transformed therewith which includes nucleic acid sequences which make possible the autocatalytic deletion of nucleotide sequences encoding an antibiotic resistance phenotype. The prokaryote can be a bacterium, and in particular a mycobacterium. Such transformed mycobacteria may be employed in vaccines, thereby eliminating the attendant risk of vaccines including antibiotic resistance markers.

L5 ANSWER 30 OF 46 USPATFULL
ACCESSION NUMBER: 1998:36365 USPATFULL
TITLE: Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
INVENTOR(S): Cohen, Irun R., Rehovot, Israel
Fridkin, Matityahu, Rehovot, Israel
Konen-Waisman, Stephanie, Tel Aviv, Israel
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Israel (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5736146		19980407	
	WO 9403208		19940217	
APPLICATION INFO.:	US 1995-379613		19950222	(8)
	WO 1993-US7096		19930728	
			19950222	PCT 371 date
			19950222	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1992-102687	19920730

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Woodward, Michael P.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 49 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 1401
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to conjugates of poorly immunogenic antigens, e.g. peptides, proteins and polysaccharides, with a synthetic peptide carrier constituting a T cell epitope derived from the sequence of human heat shock protein hsp65, or an analog thereof, said peptide or analog being capable of increasing substantially the immunogenicity of the poorly immunogenic antigen. Suitable peptides according to the invention are Pep278h, which corresponds to positions 458-474 of human hsp65, and Pep II, which corresponds to positions 437-448 of human hsp65, but in which two cysteine residues at positions 442 and 447 are replaced serine residues.

=> d 30-46 ibib ab

L5 ANSWER 30 OF 46 USPATFULL
ACCESSION NUMBER: 1998:36365 USPATFULL
TITLE: Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
INVENTOR(S): Cohen, Irun R., Rehovot, Israel
Fridkin, Matityahu, Rehovot, Israel

Konen-Waisman, Stephanie, Tel Aviv, Israel
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Israel (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5736146		19980407	
	WO 9403208		19940217	
APPLICATION INFO.:	US 1995-379613		19950222	(8)
	WO 1993-US7096		19930728	
			19950222	PCT 371 date
			19950222	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1992-102687	19920730

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Woodward, Michael P.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 49 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 1401
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to conjugates of poorly immunogenic antigens, e.g. peptides, proteins and polysaccharides, with a synthetic peptide carrier constituting a T cell epitope derived from the sequence of human heat shock protein hsp65, or an analog thereof, said peptide or analog being capable of increasing substantially the immunogenicity of the poorly immunogenic antigen. Suitable peptides according to the invention are Pep278h, which corresponds to positions 458-474 of human hsp65, and Pep II, which corresponds to positions 437-448 of human hsp65, but in which two cysteine residues at positions 442 and 447 are replaced serine residues.

L5 ANSWER 31 OF 46 USPATFULL
ACCESSION NUMBER: 1998:6790 USPATFULL
TITLE: Immunogenic composition against Bovine Viral Diarrhea Virus II glycoprotein 53 (BVDV-II gp53)
INVENTOR(S): van den Hurk, Jan, Saskatoon, Canada
Tijssen, Peter, Pointe Claire, Canada
PATENT ASSIGNEE(S): Biostar Inc., Saskatoon, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5709865		19980120	
APPLICATION INFO.:	US 1995-445746		19950522	(8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-337618, filed on 10 Nov 1994, now abandoned			

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Knode, Marian C.
ASSISTANT EXAMINER: Salimi, Ali R.
LEGAL REPRESENTATIVE: Sholtz, Charles K.Dehlinger & Associates
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1881
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the identification of Bovine Viral Diarrhea Virus group II (BVDV-II) nucleic acid sequences (e.g., gp53 sequences), to methods of using the nucleic acid sequences for detecting BVD-II virus in animal sera, to polypeptide vital antigens derived from the sequences and immunoreactive with sera from animals infected with Bovine Viral Diarrhea group II (BVD-II) virus, to polynucleotide sequences which encode these polypeptide antigens, to an expression system capable of producing the polypeptide antigens, to vaccines containing the polypeptide antigens, to methods of using the polypeptide antigens for detecting BVD-II virus antibodies in animal sera, and to antibodies directed against these polypeptide antigens.

L5 ANSWER 32 OF 46 USPATFULL
ACCESSION NUMBER: 1998:1646 USPATFULL
TITLE: Expression of heterologous proteins in drosophila cells
INVENTOR(S): Johansen, Hanne Ranch, Hojbjerg, Denmark
Van Der Straten-Ponthoz, Ariane Adrienne, Chicago, IL, United States
Rosenberg, Martin, Royersford, PA, United States(4)
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5705359		19980106	
APPLICATION INFO.:	US 1995-434095		19950503	(8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-98016, filed on 27 Jul 1993 which is a continuation of Ser. No. US 1991-681222, filed on 5 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1988-278386, filed on 1 Dec 1988, now abandoned And a continuation-in-part of Ser. No. US 1990-574563, filed on 27 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-428454, filed on 30 Oct 1989, now abandoned which is a continuation of Ser. No. US 1987-47736, filed on 8 May 1987, now abandoned			

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Garry, Sean M.
LEGAL REPRESENTATIVE: Eagle, Alissa M., Venetianer, Stephen A., Lentz, Edward T.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 1136
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for the expression of heterologous genes, under the control of a Drosophila metollothionein promoter, inserted at high copy number into Drosophila melanogaster cells.

L5 ANSWER 33 OF 46 USPATFULL
ACCESSION NUMBER: 97:99166 USPATFULL
TITLE: Expression of heterologous proteins in Drosophila cells
INVENTOR(S): Johansen, Hanne Ranch, Hojbjerg, Denmark
Van Der Straten-Ponthoz, Ariane Adrienne, Chicago, IL, United States
Rosenberg, Martin, Royersford, PA, United States(4)
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5681713		19971028	
APPLICATION INFO.:	US 1993-98016		19930727	(8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-681222, filed on 5 Apr 1991, now abandoned which is a continuation-in-part of			

Ser. No. US 1988-278386, filed on 1 Dec 1988, now abandoned And Ser. No. US 1990-574563, filed on 27 Aug 1990, now abandoned which is a continuation of Ser. No. US 1989-428454, filed on 30 Oct 1989, now abandoned which is a continuation of Ser. No. US 1987-47736, filed on 8 May 1987, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Prouty, Rebecca E.
LEGAL REPRESENTATIVE: Eagle, Alissa M., Lentz, Edward T., Venetianer, Stephen A.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 1195
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel method for expression of high levels of heterologous proteins in Drosophila cells.

L5 ANSWER 34 OF 46 USPATFULL
ACCESSION NUMBER: 97:59306 USPATFULL
TITLE: Isolation and characterization of a novel chaperone protein
INVENTOR(S): Kaye, Frederic J., Bethesda, MD, United States
Otterson, Gregory A., Columbia, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5646249		19970708
APPLICATION INFO.:	US 1994-203905		19940228 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Lau, Kawai
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 1744
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the identification and molecular characterization of the human and rat STCH chaperone protein including the corresponding gene sequence, gene fragments and protein fragments. The invention also relates antibodies to STCH and to assays to detect the presence of STCH genes, transcripts and protein in a sample.

L5 ANSWER 35 OF 46 USPATFULL
ACCESSION NUMBER: 97:38382 USPATFULL
TITLE: Mortalin and methods for determining complementation group assignment of cancer cells
INVENTOR(S): Pereira-Smith, Olivia M., Houston, TX, United States
Wadhwa, Renu, Tsukuba, Japan
PATENT ASSIGNEE(S): Baylor College of Medicine, Houston, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5627039		19970506
APPLICATION INFO.:	US 1994-214583		19940318 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
LEGAL REPRESENTATIVE: Fulbright & Jaworski L.L.P.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1277
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The intracellular distribution of mortalin is used to determine the complementation group of tumor cells. Also disclosed are the gene sequences that encode mortalin and the amino acid sequence of the mortalin proteins.

L5 ANSWER 36 OF 46 USPATFULL
ACCESSION NUMBER: 97:29572 USPATFULL
TITLE: Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
INVENTOR(S): Toback, F. Gary, Chicago, IL, United States
Lieske, John C., Evanston, IL, United States
PATENT ASSIGNEE(S): ARCH Development Corporation, Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5618917		19970408
APPLICATION INFO.:	US 1995-389005		19950215 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Reeves, Julie E.
LEGAL REPRESENTATIVE: Brinks Hofer Gilson & Lione
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1623
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An autocrine crystal adhesion inhibitor called CAI is an anionic, sialic acid-containing glycoprotein secreted by kidney epithelial cells that blocks adhesion of calcium oxalate monohydrate (COM) crystals to the cell surfaces. Persons may be classified according to risk of developing kidney stones, by measuring the amount of CAI in a biological sample. Treatment efficacy is also monitored by this method. CAI is administered in vivo to prevent nephrolithiasis. A rapid, simple assay to detect agents that inhibit adhesion of COM crystals to the surface of kidney epithelial cells is characterized.

L5 ANSWER 37 OF 46 USPATFULL
ACCESSION NUMBER: 97:1357 USPATFULL
TITLE: Recombinant BCG
INVENTOR(S): O'Donnell, Michael A., Sudbury, MA, United States
Duda, Rosemary B., Carlisle, MA, United States
DeWolf, William C., Southborough, MA, United States
Aldovini, Anna, Winchester, MA, United States
Young, Richard A., Winchester, MA, United States
PATENT ASSIGNEE(S): Beth Israel Hospital, Boston, MA, United States (U.S. corporation)
Whitehead Institute For Biomedical Research, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5591632		19970107
APPLICATION INFO.:	US 1993-96027		19930722 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-711334, filed on 6 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-367894, filed

on 19 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-361944, filed on 5 Jun 1989, now patented, Pat. No. US 5504005 which is a continuation-in-part of Ser. No. US 1988-223089, filed on 22 Jul 1988, now abandoned And a continuation-in-part of Ser. No. US 1988-216390, filed on 7 Jul 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-163546, filed on 3 Mar 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-20451, filed on 2 Mar 1987, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Vogel, Nancy T.
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1313
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired or a cytokine.

L5 ANSWER 38 OF 46 USPATFULL
ACCESSION NUMBER: 96:113834 USPATFULL
TITLE: Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins
INVENTOR(S): Stover, Charles K., Silver Spring, MD, United States
PATENT ASSIGNEE(S): MedImmune, Inc., Gaithersburg, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5583038		19961210
APPLICATION INFO.:	US 1992-977630		19921117 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-780261, filed on 21 Oct 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fleisher, Mindy
ASSISTANT EXAMINER: Carter, Philip W.
LEGAL REPRESENTATIVE: Olstein, Elliot M.
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 60 Drawing Figure(s); 64 Drawing Page(s)
LINE COUNT: 2112
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An expression vector for expressing a protein or polypeptide in a bacterium, which comprises a first DNA sequence encoding at least a secretion signal of a lipoprotein, and a second DNA sequence encoding a protein or fragment thereof, or polypeptide or peptide heterologous to the bacterium which expresses the protein or fragment thereof, or polypeptide or peptide. The bacterium expresses a fusion protein a lipoprotein or lipoprotein segment and the protein or fragment thereof, or polypeptide or peptide heterologous to the bacterium which expresses the protein or fragment thereof, or polypeptide or peptide. Such expression vectors increase the immunogenicity of the protein or fragment thereof, or polypeptide or peptide by enabling the protein or fragment thereof, or polypeptide or peptide to be expressed on the surface of the bacterium. Bacteria which may be transformed with the expression vector include mycobacteria such as BCG. The expression vectors of the present invention may be employed in the formation of live bacterial vaccines against Lyme disease wherein the bacteria express a surface protein of Borrelia burgdorferi, the causative agent of Lyme disease.

L5 ANSWER 39 OF 46 USPATFULL
ACCESSION NUMBER: 96:111449 USPATFULL
TITLE: Delivery of exogenous DNA sequences in a mammal
INVENTOR(S): Felgner, Philip L., Rancho Santa Fe, CA, United States
Wolff, Jon A., Madison, WI, United States
Rhodes, Gary H., Leucadia, CA, United States
Malone, Robert W., Chicago, IL, United States
Carson, Dennis A., Del Mar, CA, United States
PATENT ASSIGNEE(S): VICAL Incorporated, San Diego, CA, United States (U.S. corporation)
Wisconsin Alumni Research Foundation, Dane, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5580859		19961203
APPLICATION INFO.:	US 1994-215405		19940318 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-846827, filed on 6 Mar 1992, now abandoned which is a division of Ser. No. US 1990-496991, filed on 21 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-467881, filed on 19 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-326305, filed on 21 Mar 1989, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Stone, Jacqueline M.
ASSISTANT EXAMINER: Crouch, Deborah
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 2572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polynucleotide sequences, comprising DNA and RNA molecules can be directly administered, for example by injection, to tissues, such as muscle, and expressed as a protein, polypeptide or polypeptide. The polynucleotides can be contained within liposomes or the polynucleotides can free from association with transfection-facilitating proteins, viral particles, liposomal formulations, charged lipids and calcium phosphate precipitating agents.

L5 ANSWER 40 OF 46 USPATFULL
ACCESSION NUMBER: 96:108677 USPATFULL
TITLE: Diagnosis and treatment of insulin dependent diabetes mellitus
INVENTOR(S): Cohen, Irun R., Rehovot, Israel
Elias, Dana, Rehovot, Israel
Markovits, Doron, Rehovot, Israel
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5578303		19961126
APPLICATION INFO.:	US 1993-151052		19931112 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-751448, filed on 29 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-493127, filed on 14 Mar 1990, now

abandoned which is a continuation-in-part of Ser. No. US 1989-371249, filed on 26 Jun 1989, now patented, Pat. No. US 5114844 which is a continuation-in-part of Ser. No. US 1989-322864, filed on 14 Mar 1989, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Cunningham, Thomas M.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A 65 KD heat shock protein, proteins cross-reactive therewith, antibodies thereto or T cells specific thereto can be used for detecting in humans the existence of, a tendency to develop, or the initiation of a process leading to insulin dependent diabetes mellitus. Antibodies to hsp65 can be used to detect the hsp65 molecule in blood or urine. The hsp65 molecule of any species, or any other substance immunologically cross-reactive therewith, when administered with a tolerogenic carrier, can be used for the prevention or treatment of IDDM prior to development of clinical symptoms thereof. T cells, active fragments thereof or the receptor peptide thereof can also be used for prevention or treatment of IDDM.

L5 ANSWER 41 OF 46 USPATFULL
ACCESSION NUMBER: 96:77699 USPATFULL
TITLE: Expression of heterologous proteins in Drosophila cells
INVENTOR(S): Johansen, Hanne R., Hojbjerg, Denmark
Van Der Straten-Ponthoz, Ariane A., Chicago, IL, United States
Rosenberg, Martin, Royersford, PA, United States(4)
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5550043		19960827
APPLICATION INFO.:	US 1995-433178		19950503 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-98016, filed on 27 Jul 1993 which is a continuation-in-part of Ser. No. US 1988-278386, filed on 1 Dec 1988, now abandoned And Ser. No. US 1990-574563, filed on 27 Aug 1990, now abandoned which is a continuation of Ser. No. US 1989-428454, filed on 30 Oct 1989 which is a continuation of Ser. No. US 1987-47736, filed on 8 May 1987
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
LEGAL REPRESENTATIVE: Sutton, Jeffrey A., Jervis, Herbert H., Lentz, Edward T.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 1153
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel method for expression of high levels of heterologous proteins in Drosophila cells.

L5 ANSWER 42 OF 46 USPATFULL
ACCESSION NUMBER: 96:55678 USPATFULL
TITLE: In vitro activation of cytotoxic t-cells using insect cells expressing human class I MHC and .beta.2-microglobulin
INVENTOR(S): Peterson, Per A., La Jolla, CA, United States
Jackson, Michael, Del Mar, CA, United States
Langlade-Demoyen, Pierre, Del Mar, CA, United States
PATENT ASSIGNEE(S): Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5529921		19960625
APPLICATION INFO.:	US 1994-209797		19940310 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1992-841662, filed on 19 Feb 1992, now patented, Pat. No. US 5314813
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Adams, Donald E.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 3968
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CD8 cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human .beta.2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.

L5 ANSWER 43 OF 46 USPATFULL
ACCESSION NUMBER: 95:80215 USPATFULL
TITLE: Heat shock/stress response proteins and prognosis in cancer
INVENTOR(S): McGuire, deceased, William L., late of San Antonio, TX, United States by John W. Robb, legal representative
Clark, Gary M., San Antonio, TX, United States
Chamness, Gary C., San Antonio, TX, United States
Tandon, Atul K., San Ramon, TX, United States
Fuqua, Suzanne A., San Antonio, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5447843		19950905	
	WO 9116632		19911031	
APPLICATION INFO.:	US 1992-949630		19921125	(7)
	WO 1991-US2536		19910412	
			19921125	PCT 371 date
			19921125	PCT 102(e) date

DISCLAIMER DATE: 20100223
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-509377, filed on 12 Apr 1990, now patented, Pat. No. US 5188964
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 15
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of predicting disease-free survival in cancer patients by relating the number and amount of stress response proteins in cancer tissue to the probability of tumor recurrence. Particular heat shock/stress response proteins useful in the determination of tumor recurrence are the stress response proteins, **hsp70**, hsp90, hsp27, and glucose regulated protein grp94. Specific levels of the stress response proteins relative to an internal standard are identified, above which the probability of tumor recurrence is highly significant. Kit methods are disclosed which could enable determination of the stress proteins by an antibody assay.

L5 ANSWER 44 OF 46 USPATFULL

ACCESSION NUMBER:	94:44555 USPATFULL
TITLE:	Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
INVENTOR(S):	Peterson, Per A., LaJolla, CA, United States Jackson, Michael, Del Mar, CA, United States Langlade-Demoyen, Pierre, Del Mar, CA, United States
PATENT ASSIGNEE(S):	Scripps Research Institute, LaJolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5314813		19940524
APPLICATION INFO.:	US 1992-841662		19920219 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hill, Jr., Robert J.		
ASSISTANT EXAMINER:	Allen, Marianne P.		
LEGAL REPRESENTATIVE:	Logan, April C., Liebeschuetz, Joe, Smith, William M.		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 19 Drawing Page(s)		
LINE COUNT:	3911		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CD8 cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human .beta.2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.

L5 ANSWER 45 OF 46 USPATFULL

ACCESSION NUMBER:	93:100493 USPATFULL
TITLE:	Insect-specific paralytic neurotoxin genes for use in biological insect control: methods and compositions
INVENTOR(S):	Tomalski, Michael D., Athens, GA, United States Miller, Lois K., Athens, GA, United States
PATENT ASSIGNEE(S):	University of Georgia Research Foundation, Inc., Athens, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5266317		19931130
APPLICATION INFO.:	US 1990-593657		19901004 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Furman, Keith C.		
LEGAL REPRESENTATIVE:	Greenlee and Winner		
NUMBER OF CLAIMS:	61		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	2085		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Genes encoding insect-specific paralytic neurotoxins, particularly those of insect-parasitic mites, including Pyemotes, are described. Recombinant DNA molecules in which the neurotoxin coding sequences are placed under the control of heterologous promoters are also described. Such molecules are useful for the development of biological insect control agents which produce insect-toxic levels of the neurotoxin. Specifically described are genetically altered baculoviruses which produce insect-specific paralytic neurotoxins and which display improved toxic effect on insects. Insect-toxic compositions are also provided. Methods of insect control using these neurotoxin genes, methods for production of neurotoxins in cells, and methods of production of insect control agents are described.

L5 ANSWER 46 OF 46 USPATFULL

ACCESSION NUMBER:	93:14496 USPATFULL
TITLE:	Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
INVENTOR(S):	McGuire, William L., San Antonio, TX, United States Tandon, Atul K., San Antonio, TX, United States Clark, Gary M., San Antonio, TX, United States Chamness, Gary C., San Antonio, TX, United States
PATENT ASSIGNEE(S):	Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5188964		19930223
APPLICATION INFO.:	US 1990-509377		19900412 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Housel, James C.		
ASSISTANT EXAMINER:	Chan, William		
LEGAL REPRESENTATIVE:	Arnold, White & Durkee		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	1495		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of predicting disease-free survival in cancer patients by relating the number and amount of stress response proteins in the cancer tissue to the probability of tumor recurrence. Particular heat shock/stress response proteins useful in the determination of tumor recurrence are the stress response proteins, **hsp70**, hsp90, hsp27, and glucose regulated protein grp94. Specific levels of the stress response proteins are identified, above which the probability of tumor recurrence is highly signficant. Kit methods are disclosed which could enable determination of the stress proteins by an antibody assay.

=> d his

(FILE 'HOME' ENTERED AT 07:31:47 ON 11 SEP 2002)

FILE 'USPATFULL' ENTERED AT 07:32:03 ON 11 SEP 2002

L1 820 S HSP70 OR HEAT SHOCK PROTEIN 70
L2 340 S L1 AND ADJUVANT
L3 340 DUP REM L2 (0 DUPLICATES REMOVED)
L4 340 S L3

```
L5           46 S L3 NOT PY=>1999

=> s l2 and pharmaceutic
           523 PHARMACEUTIC
          1309 PHARMACEUTICS
          1800 PHARMACEUTIC
                 (PHARMACEUTIC OR PHARMACEUTICS)
L6            0 L2 AND PHARMACEUTIC

=>

=> s l2 and pharmaceutical?
        144495 PHARMACEUTICAL?
L7          266 L2 AND PHARMACEUTICAL?

=> s l7 and cancer
         52128 CANCER
         15572 CANCERS
         54070 CANCER
                 (CANCER OR CANCERS)
L8          210 L7 AND CANCER

=> s l8 and administer?
        142884 ADMINISTER?
L9          207 L8 AND ADMINISTER?

=> s l9 and treat?
        787080 TREAT?
L10         207 L9 AND TREAT?

=> s l10 not py=>1999
        816008 PY=>1999
L11          14 L10 NOT PY=>1999

=> d 1-14 ibib and ab
'AND' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS -------- AB
ALL -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
             EXF, ARTU
ALLG ------- ALL plus PAGE.DRAW
BIB -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
             PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT
BIB.EX ----- BIB for original and latest publication
BIBG ------- BIB plus PAGE.DRAW
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE".  BROWSE must
             entered on the same line as DISPLAY, e.g., D BROWSE.
CAS -------- OS, CC, SX, ST, IT
CBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS
DALL ------- ALL, delimited for post-processing
FP --------- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
             PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL,
             NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,
             CLMN, DRWN, AB
FP.EX ------ FP for original and latest publication
FPALL ------ PI, TI, IN, INA, PA, PAA, PAT, PETRM, DCD, AI,
             RLI, PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL, NCLM,
             NCLS, EXF, REP, REN,ARTU, EXNAM, LREP, CLMN, DRWN, AB,
             PARN, SUMM, DRWD, DETD, CLM
FPBIB ------ PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
             RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN
FHITSTR ---- HIT RN, its text modification, its CA index name, and
             its structure diagram
FPG -------- FP plus PAGE.DRAW
GI --------- PN and page image numbers
HIT -------- All fields containing hit terms
HITRN ------ HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
             its structure diagram
IABS ------- ABS, indented with text labels
IALL ------- ALL, indented with text labels
IALLG ------ IALL plus PAGE.DRAW
IBIB ------- BIB, indented with text labels
IBIB.EX ---- IBIB for original and latest publication
IBIBG ------ IBIB plus PAGE.DRAW
IMAX ------- MAX, indented with text labels
IMAX.EX ---- IMAX for original and latest publication
IND -------- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
             EXF, ARTU, OS, CC, SX, ST, IT
ISTD ------- STD, indented with text labels
KWIC ------- All hit terms plus 20 words on either side
MAX -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
             EXF, ARTU OS, CC, SX, ST, IT
MAX.EX ----- MAX for original and latest publication
OCC -------- List of display fields containing hit terms
SBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
             DT, FS, LN.CNT
SCAN ------- AN, TI, NCL, NCLM, NCLS, IC, ICM, ICS (random display
             without answer number.  SCAN must be entered on the
             same line as DISPLAY, e.g., D SCAN)
STD -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
             DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,
             IC, ICM, ICS, EXF (STD is the default)
STD.EX ----- STD for original and latest publication
TRIAL ------ AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,
             ICM, ICS

ENTER DISPLAY FORMAT (STD):end

=> d his

     (FILE 'HOME' ENTERED AT 07:31:47 ON 11 SEP 2002)

     FILE 'USPATFULL' ENTERED AT 07:32:03 ON 11 SEP 2002
L1           820 S HSP70 OR HEAT SHOCK PROTEIN 70
L2           340 S L1 AND ADJUVANT
L3           340 DUP REM L2 (0 DUPLICATES REMOVED)
L4           340 S L3
L5            46 S L3 NOT PY=>1999
L6             0 S L2 AND PHARMACEUTIC
L7           266 S L2 AND PHARMACEUTICAL?
L8           210 S L7 AND CANCER
L9           207 S L8 AND ADMINISTER?
L10          207 S L9 AND TREAT?
L11           14 S L10 NOT PY=>1999

=> d l11 1-14 ibib ab
```

L11 ANSWER 1 OF 14 USPATFULL

ACCESSION NUMBER: 1998:151078 USPATFULL
TITLE: Vertebrate embryonic pattern-inducing proteins, and uses related thereto
INVENTOR(S): Ingham, Philip W., Summertown, England
McMahon, Andrew P., Lexington, MA, United States
Tabin, Clifford J., Cambridge, MA, United States
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5844079		19981201
APPLICATION INFO.:	US 1994-356060		19941214 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-176427, filed on 30 Dec 1993
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Sorensen, Kenneth H.
LEGAL REPRESENTATIVE: Vincent, Matthew P., Arnold, Beth E.Foley, Hoag & Eliot LLP
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 7618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.

L11 ANSWER 2 OF 14 USPATFULL

ACCESSION NUMBER: 1998:143661 USPATFULL
TITLE: Compositions and methods using complexes of heat shock proteins and antigenic molecules for the **treatment** and prevention of neoplastic diseases
INVENTOR(S): Srivastava, Pramod K., Riverdale, NY, United States
PATENT ASSIGNEE(S): Fordham University, Bronx, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5837251		19981117
APPLICATION INFO.:	US 1995-527391		19950913 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Bansal, Gee Tha D.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1,8,16
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2361
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions for eliciting an immune response and the prevention and **treatment** of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise **administering** a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10-600 micrograms for complexes comprising **hsp70**, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96. The invention also provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MHC Class I-restricted CD8+ cytotoxic T lymphocytes specific to the tumor. Methods of purifying **hsp70**-peptide complexes are also provided.

L11 ANSWER 3 OF 14 USPATFULL

ACCESSION NUMBER: 1998:138682 USPATFULL
TITLE: Polynucleotides encoding a cofactor A-like protein
INVENTOR(S): Hillman, Jennifer L., San Jose, CA, United States
Goli, Surya K., Sunnyvale, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834239		19981110
APPLICATION INFO.:	US 1997-825782		19970408 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kemmerer, Elizabeth C.
ASSISTANT EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Mohan-Peterson, Sheela, Billings, Lucy J.Incyte Pharmaceuticals, Inc.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a human cofactor A-like protein (COAPR) and polynucleotides which identify and encode COAPR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for **treating** disorders associated with expression of COAPR.

L11 ANSWER 4 OF 14 USPATFULL

ACCESSION NUMBER: 1998:138427 USPATFULL
TITLE: Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
INVENTOR(S): Paoletti, Enzo, Delmar, NY, United States
Tartaglia, James, Schenectady, NY, United States
Cox, William I., Troy, NY, United States
PATENT ASSIGNEE(S): Virogenetics Corporation, Troy, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5833975		19981110
APPLICATION INFO.:	US 1994-184009		19940119 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-7115, filed on 21 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-847951, filed on 6 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-713967, filed on 11 Jun 1991, now abandoned which is a

continuation-in-part of Ser. No. US 1991-666056, filed on 7 Mar 1991, now abandoned , said Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 1991-805567, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-638080, filed on 7 Jan 1991, now abandoned , said Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 1992-847977, filed on 3 Mar 1992, now abandoned which is a division of Ser. No. US 1990-478179, filed on 14 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-320471, filed on 8 Mar 1989, now patented, Pat. No. US 5155020

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Crouch, Deborah
LEGAL REPRESENTATIVE: Frommer Lawerence & Haug LLP, Frommer, William S., Kowalski, Thomas J.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 46 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 8834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Attenuated vaccinia or canarypox recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IFN.gamma.; IL-4; GMCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for **cancer** therapy.

L11 ANSWER 5 OF 14 USPATFULL
ACCESSION NUMBER: 1998:134628 USPATFULL
TITLE: Compositions and methods for the **treatment** and growth inhibition of **cancer** using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
INVENTOR(S): Srivastava, Pramod K., Riverdale, NY, United States
PATENT ASSIGNEE(S): Fordham University, Bronx, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5830464		19981103
APPLICATION INFO.:	US 1997-796316		19970207 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: VanderVegt, F. Pierre
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
LINE COUNT: 2332
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions for eliciting an immune response and the prevention and **treatment** of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise **administering** a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule in combination with **administering** antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex when **administered** intradermally are in the range of 0.1 to 9.0 micrograms for complexes comprising **hsp70**, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96. In another embodiment, the effective amounts of the complex when **administered** subcutaneously are in the range of 10 to 600 micrograms for complexes comprising **hsp70**, 50 to 5000 micrograms for hsp90, and 10 to 600 micrograms for gp96.

L11 ANSWER 6 OF 14 USPATFULL
ACCESSION NUMBER: 1998:119003 USPATFULL
TITLE: Heat shock-like protein
INVENTOR(S): Hillman, Jennifer L., San Jose, CA, United States
Shah, Purvi, Sunnyvale, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5814481		19980929
APPLICATION INFO.:	US 1997-846134		19970425 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Bugalsky, Gabriele E.
LEGAL REPRESENTATIVE: Billings, Lucy J.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1943
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel heat shock-like protein (HSPRO) and polynucleotides which identify and encode HSPRO. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for **treating** disorders associated with expression of HSPRO.

L11 ANSWER 7 OF 14 USPATFULL
ACCESSION NUMBER: 1998:111956 USPATFULL
TITLE: Inhibitors of IMPDH enzyme
INVENTOR(S): Armistead, David M., Maynard, MA, United States
Badia, Michael C., Bedford, MA, United States
Bemis, Guy W., Arlington, MA, United States
Bethiel, Randy S., Allston, MA, United States
Frank, Catharine A., Marlborough, MA, United States
Novak, Perry M., Milford, MA, United States
Ronkin, Steven M., Watertown, MA, United States
Saunders, Jeffrey O., Acton, MA, United States
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5807876		19980915
APPLICATION INFO.:	US 1996-636361		19960423 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Govindaswamy, N.

NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel class of compounds which are IMPDH inhibitors. This invention also relates to **pharmaceutical** compositions comprising these compounds. The compounds and **pharmaceutical** compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as agents for immunosuppression. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.

L11 ANSWER 8 OF 14 USPATFULL
ACCESSION NUMBER: 1998:101540 USPATFULL
TITLE: Human protein disulfide isomerase
INVENTOR(S): Braxton, Scott Michael, San Mateo, CA, United States
Murry, Lynn E., Pórtola Valley, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5798249		19980825
APPLICATION INFO.:	US 1996-650275		19960516 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-649740, filed on 15 May 1996
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Saidha, Tekchand
LEGAL REPRESENTATIVE: Billings, Lucy J.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2291
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a polynucleotide (pdih) the partial sequence for which was initially isolated from a lung cDNA library and which identifies and encodes a novel human protein disulfide isomerase (PDIH). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PDIH. The invention also provides for the use of purified PDIH and its agonists in the commercial production of recombinant proteins and in **pharmaceutical** compositions for the **treatment** of diseases associated with the abnormal expression of PDIH. Additionally, the invention provides for the use of antisense molecules to pdih or inhibitors of PDIH in **pharmaceutical** compositions for **treatment** of diseases resulting secretion of PDIH. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of pdih, or anti-PDIH antibodies which specifically bind to the polypeptide, PDIH.

L11 ANSWER 9 OF 14 USPATFULL
ACCESSION NUMBER: 1998:92162 USPATFULL
TITLE: Vertebrate embryonic pattern-inducing proteins and uses related thereto
INVENTOR(S): Ingham, Philip W., Summertown, England
McMahon, Andrew P., Lexington, MA, United States
Tabin, Clifford J., Cambridge, MA, United States
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5789543		19980804
APPLICATION INFO.:	US 1993-176427		19931230 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Sorensen, Kenneth A.
LEGAL REPRESENTATIVE: Vincent, Matthew P., Arnold, Beth E.Foley, Hoag & Eliot LLP
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 4235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.

L11 ANSWER 10 OF 14 USPATFULL
ACCESSION NUMBER: 1998:88652 USPATFULL
TITLE: Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
INVENTOR(S): Artavanis-Tsakonas, Spyridon, Hamden, CT, United States
Fehon, Richard Grant, Durham, NC, United States
Zagouras, Panayiotis, New Haven, CT, United States
Blaumueller, Christine Marie, New Haven, CT, United States
PATENT ASSIGNEE(S): Yale University, New Haven, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5786158		19980728
APPLICATION INFO.:	US 1993-83590		19930625 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-955012, filed on 30 Sep 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-879038, filed on 30 Apr 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 2
NUMBER OF DRAWINGS: 70 Drawing Figure(s); 68 Drawing Page(s)
LINE COUNT: 4658
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to diagnostic methods and compositions for detection of malignancy or nervous system disorders based on the level of Notch proteins or nucleic acids. Therapeutic methods and methods of inhibiting Notch expression are also provided.

L11 ANSWER 11 OF 14 USPATFULL
ACCESSION NUMBER: 1998:51728 USPATFULL
TITLE: Deltex proteins
INVENTOR(S): Artavanis-Tsakonas, Spyridon, Hamden, CT, United States
Busseau, Isabelle, Bures-Sur-Yvette, France
Diederich, Robert J., New Haven, CT, United States

Xu, Tian, Guilford, CT, United States
Matsuno, Kenji, New Haven, CT, United States
PATENT ASSIGNEE(S): Yale University, New Haven, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5750652		19980512
APPLICATION INFO.:	US 1994-185432		19940121 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Sorensen, Kenneth A.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 58 Drawing Figure(s); 40 Drawing Page(s)
LINE COUNT: 4194
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to amino acid sequences of the encoded deltex protein. The invention further relates to fragments and other derivatives, and analogs, of deltex proteins. In specific embodiments, the invention relates to deltex protein derivatives and analogs of the invention which are functionally active, or which comprise one or more domains of a deltex protein, including but not limited to the Gln-rich clusters, SH3 binding domains, domains which mediate binding to Notch or to a Notch derivative containing Notch cdc10/SW16/ankyrin ("ANK") repeats, domains which mediate binding to a second deltex protein, or any combination of the foregoing. The present invention also relates to compositions based on deltex proteins.

L11 ANSWER 12 OF 14 USPATFULL
ACCESSION NUMBER: 1998:51204 USPATFULL
TITLE: Immunotherapeutic stress protein-peptide complexes against **cancer**
INVENTOR(S): Srivastava, Pramod K., Riverdale, NY, United States
PATENT ASSIGNEE(S): Mount Sinai School of Medicine Of The City University of New York, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5750119		19980512
APPLICATION INFO.:	US 1994-315892		19940930 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-180685, filed on 13 Jan 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1,2
LINE COUNT: 1097
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a method for inhibiting the proliferation of a tumor in a mammal. The method involves the steps of (a) isolating a stress protein-peptide complex from tumor cells previously removed from the mammal and (b) **administering** the isolated stress protein-peptide complex back to the mammal in order to stimulate in the mammal an immune response against the tumor from which the complex was isolated. Stress protein-peptide complexes having particular utility in the practice of the instant invention include the **Hsp70** -peptide, Hsp90-peptide and gp96-peptide complexes.

L11 ANSWER 13 OF 14 USPATFULL
ACCESSION NUMBER: 97:29572 USPATFULL
TITLE: Methods and compositions for detecting and **treating** kidney diseases associated with adhesion of crystals to kidney cells
INVENTOR(S): Toback, F. Gary, Chicago, IL, United States
Lieske, John C., Evanston, IL, United States
PATENT ASSIGNEE(S): ARCH Development Corporation, Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5618917		19970408
APPLICATION INFO.:	US 1995-389005		19950215 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Reeves, Julie E.
LEGAL REPRESENTATIVE: Brinks Hofer Gilson & Lione
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1623
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An autocrine crystal adhesion inhibitor called CAI is an anionic, sialic acid-containing glycoprotein secreted by kidney epithelial cells that blocks adhesion of calcium oxalate monohydrate (COM) crystals to the cell surfaces. Persons may be classified according to risk of developing kidney stones, by measuring the amount of CAI in a biological sample. **Treatment** efficacy is also monitored by this method. CAI is **administered** in vivo to prevent nephrolithiasis. A rapid, simple assay to detect agents that inhibit adhesion of COM crystals to the surface of kidney epithelial cells is characterized.

L11 ANSWER 14 OF 14 USPATFULL
ACCESSION NUMBER: 96:111449 USPATFULL
TITLE: Delivery of exogenous DNA sequences in a mammal
INVENTOR(S): Felgner, Philip L., Rancho Santa Fe, CA, United States
Wolff, Jon A., Madison, WI, United States
Rhodes, Gary H., Leucadia, CA, United States
Malone, Robert W., Chicago, IL, United States
Carson, Dennis A., Del Mar, CA, United States
PATENT ASSIGNEE(S): VICAL Incorporated, San Diego, CA, United States (U.S. corporation)
Wisconsin Alumni Research Foundation, Dane, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5580859		19961203
APPLICATION INFO.:	US 1994-215405		19940318 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-846827, filed on 6 Mar 1992, now abandoned which is a division of Ser. No. US 1990-496991, filed on 21 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-467881, filed on 19 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-326305, filed on 21 Mar 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Stone, Jacqueline M.
ASSISTANT EXAMINER: Crouch, Deborah
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 2572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polynucleotide sequences, comprising DNA and RNA molecules can be directly **administered**, for example by injection, to tissues, such as muscle, and expressed as a protein, polypeptide or polypeptide. The polynucleotides can be contained within liposomes or the polynucleotides can free from association with transfection-facilitating proteins, viral particles, liposomal formulations, charged lipids and calcium phosphate precipitating agents.